HK Stock Market Move | EVEREST MED (01952) surged over 5% in early trading, and the new drug application for Sinto-PSVT has been approved in China.

EVEREST MED (01952) rose over 5% in early trading. As of the time of this report, it has increased by 4.73%, reaching HKD 32.78, with a transaction volume of HKD 151 million. In terms of news, on September 3, EVEREST MED announced that the National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for Sinopito (Aicupam Nasal Spray) for the treatment of acute symptom episodes of paroxysmal supraventricular tachycardia (PSVT) in adults, aiming to restore normal sinus rhythm. Sinopito received approval from the U.S. Food and Drug Administration (FDA) in December 2025, becoming the first and only innovative therapy approved for the treatment of acute symptom episodes of adult PSVT in over 30 years. Its approval in China means that this innovative therapy is officially entering the Chinese market, marking EVEREST MED's first approved product in the field of cardiovascular diseases.